SCHEMBL5500740

SCHEMBL5500740

CCCCS(=O)(=O)c1cc(Oc2ccc(Cl)cc2F)c(CCN)cc1F

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
KCNH2 Q12809 1/20 0.39
SLC6A3 Q01959 1/20 0.39
HTR2C P28335 5/20 0.37
HTR2A P28223 4/20 0.37
HTR2B P41595 3/20 0.37
PTGDR2 Q9Y5Y4 4/20 0.37
PTGDR Q13258 2/20 0.37
GLA P06280 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33
CCR2 P41597 1/20 0.33
EPAS1 Q99814 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5505055 0.94 SOS1 (0.41) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5500735 0.86 SLC6A4 (0.54) SLC6A2SLC6A4KCNH2SLC6A3HTR2A
SCHEMBL5504336 0.84 SOS1 (0.44) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5505050 0.80 SLC6A4 (0.56) SLC6A2SLC6A4KCNH2SLC6A3HTR2A
SCHEMBL5503983 0.76 SLC6A4 (0.50) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5507294 0.75 SLC6A4 (0.48) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5502812 0.75 SOS1 (0.47) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5497245 0.74 SLC6A4 (0.49) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5504724 0.73 SLC6A2 (0.42) SOS1SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL5503317 0.72 SLC6A4 (0.47) SOS1SLC6A2SLC6A4KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791807-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS Pfizer Products Incorporated (US) 2007-06-06 EP claimed
WO-2006027684-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS PFIZER PRODUCTS INC. (US) 2006-03-16 WO claimed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 US claimed
EP-1791807-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS Pfizer Products Incorporated (US) 2007-06-06 EP disclosed
WO-2006027684-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS PFIZER PRODUCTS INC. (US) 2006-03-16 WO disclosed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058361-A1 Therapeutic diphenyl ether ligands HTR2B, HTR2C, HTR3B SOS1 3837/4885SLC6A2 386/4885SLC6A4 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.